Astria Therapeutics, Inc. Sample Contracts

May 13th, 2015 · Common Contracts · 687 similar
Catabasis Pharmaceuticals IncINDEMNIFICATION AGREEMENT

THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [ ], 20 [ ] between Catabasis Pharmaceuticals, Inc., a Delaware corporation (the “Company” which term shall include where appropriate, any Entity (as hereinafter defined) controlled by or under the control of Catabasis Pharmaceuticals, Inc.), and [name] (“Indemnitee”).

January 30th, 2020 · Common Contracts · 213 similar
Catabasis Pharmaceuticals Inc4,600,000 Shares of Common Stock CATABASIS PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT

Catabasis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Oppenheimer & Co. Inc., as sole underwriter (the “Underwriter”), an aggregate of 4,600,000 authorized but unissued shares (the “Firm Shares”) of Common Stock, par value $0.001 per share, of the Company (the “Common Stock”). In addition, the Company proposes to grant to the Underwriter an option to purchase up to an additional 690,000 shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called “Shares.”

May 14th, 2019 · Common Contracts · 193 similar
Catabasis Pharmaceuticals IncCATABASIS PHARMACEUTICALS, INC. COMMON STOCK SALES AGREEMENT

Catabasis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:

June 11th, 2015 · Common Contracts · 78 similar
Catabasis Pharmaceuticals IncCATABASIS PHARMACEUTICALS, INC. SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of the 17th day of March, 2015, as amended on June 10, 2015, by and among Catabasis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.

June 11th, 2015 · Common Contracts · 57 similar
Catabasis Pharmaceuticals IncCatabasis Pharmaceuticals, Inc. Shares Common Stock ($0.001 par value per share) Underwriting Agreement

Catabasis Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, shares of common stock, $0.001 par value per share (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plura

June 30th, 2021 · Common Contracts · 47 similar
Catabasis Pharmaceuticals IncOPEN MARKET SALE AGREEMENTSM
May 13th, 2015 · Common Contracts · 27 similar
Catabasis Pharmaceuticals IncContract

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW, OR SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION CAN BE MADE IN COMPLIANCE WITH RULE 144 OF THE ACT, OR IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION.

January 23rd, 2015 · Common Contracts · 15 similar
Catabasis Pharmaceuticals IncINDEMNIFICATION AGREEMENT

THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [ ] between Catabasis Pharmaceuticals, Inc., a Delaware corporation (the “Company,” which term shall include where appropriate, any Entity (as hereinafter defined) controlled by or under the control of Catabasis Pharmaceuticals, Inc.), and [ ] (“Indemnitee”).

September 23rd, 2016 · Common Contracts · 12 similar
Catabasis Pharmaceuticals IncCatabasis Pharmaceuticals, Inc. 2,500,000 Shares Common Stock ($0.001 par value per share) Underwriting Agreement

Catabasis Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to Cowen and Company, LLC (the “Underwriter”), 2,500,000 shares of common stock, $0.001 par value per share (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriter an option to purchase up to 375,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). Certain terms used herein are defined in Section 20 hereof. Any reference herein to the Registration Statement, the Base Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form S-3 which were filed under the Exchange Act on or before the Effective Date of the Registration

March 11th, 2021 · Common Contracts · 6 similar
Catabasis Pharmaceuticals IncREGISTRATION RIGHTS AGREEMENT

This Registration Rights Agreement (this “Agreement”) is dated as of January 28, 2021, by and among Catabasis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

January 29th, 2021 · Common Contracts · 3 similar
Catabasis Pharmaceuticals IncREGISTRATION RIGHTS AGREEMENT

This Registration Rights Agreement (this “Agreement”) is dated as of January 28, 2021, by and among Catabasis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

May 13th, 2015 · Common Contracts · 2 similar
Catabasis Pharmaceuticals IncCATABASIS PHARMACEUTICALS, INC. Nonstatutory Stock Option Agreement Granted Under 2008 Equity Incentive Plan
May 13th, 2015 · Common Contracts · 2 similar
Catabasis Pharmaceuticals IncCATABASIS PHARMACEUTICALS, INC. Incentive Stock Option Agreement Granted Under 2008 Equity Incentive Plan
March 11th, 2021 · Common Contracts · 2 similar
Catabasis Pharmaceuticals IncCATABASIS PHARMACEUTICALS, INC. ASSUMED WARRANT TO PURCHASE SHARES OF PREFERRED STOCK

This Assumed Warrant (this “Warrant”) is issued to Viridian, LLC (the “Holder”) by Catabasis Pharmaceuticals, Inc., a Delaware corporation (the “Company”). This Warrant and the Assumed Warrant to Purchase Shares of Common Stock of even date herewith being issued by the Company to the Holder (the “Assumed Common Stock Warrant”) are being issued pursuant to Section 7(b) of the Warrant to Purchase Shares of Common Stock issued by Quellis Biosciences, Inc. (“Quellis”) to the Holder as of December 14, 2020 (the “Original Warrant”) to effectuate the assumption by the Company of the Original Warrant pursuant to Section 3.2(b) of the Agreement and Plan of Merger, dated as of the date hereof (the “Merger Agreement”), among the Company, Quellis, Cabo Merger Sub I, Inc. and Cabo Merger Sub II, LLC. Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Merger Agreement.

May 13th, 2015 · Common Contracts · 2 similar
Catabasis Pharmaceuticals IncAMENDED AND RESTATED EMPLOYMENT AGREEMENT

THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT dated as of April 7, 2010 (the “Agreement”) is by and between Catabasis Pharmaceuticals, Inc. (the “Company”), a Delaware corporation with its principal place of business at 161 First Street, Suite 1, Cambridge, Massachusetts, and Jill C. Milne (the “Executive”).

June 3rd, 2015 · Common Contracts · 2 similar
Catabasis Pharmaceuticals IncCATABASIS PHARMACEUTICALS, INC. NONSTATUTORY STOCK OPTION AGREEMENT

This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.

May 13th, 2015 · Common Contracts · 2 similar
Catabasis Pharmaceuticals IncTHIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT

Catabasis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that [ ], or [his/her] registered assigns (the “Registered Holder”), is entitled, subject to the terms and conditions set forth below, to purchase from the Company, at any time or from time to time on or after the closing date of the Company’s Qualified Financing (as defined below) and on or before 5:00 p.m. (Eastern Standard Time) on the sixth anniversary of the closing date of the Company’s Qualified Financing, that number of shares of Common Stock, $0.001 par value per share, of the Company (the “Common Stock”) equal to the quotient of (A) $[ ], divided by (B) the Qualified Financing Purchase Price (as defined below). This Warrant shall be exercisable for a purchase price per share equal to the fair market value of the Common Stock at the time of the closing of the Qualified Financing. The shares purchasable upon exercise of this Warrant, and the purchase price per share, ea

November 7th, 2019
Catabasis Pharmaceuticals IncSUBLEASE

This Sublease (the “Sublease”) is entered into effective as of September 9, 2019 (the “Effective Date”) by and between Allied Minds, LLC, a Delaware limited liability company (“Sublandlord”), and Catabasis Pharmaceuticals, Inc., a Delaware corporation (“Subtenant”).

November 7th, 2016
Catabasis Pharmaceuticals IncTHIRD AMENDMENT OF LEASE

THIS THIRD AMENDMENT OF LEASE (this “Amendment”) is made as of this 3rd day of November 2016, by and between DWF IV ONE KENDALL, LLC, a Delaware limited liability company having an address c/o Divco West Real Estate Services, Inc., One Kendall Square, Cambridge, Massachusetts 02139, Attention: Property Manager (“Landlord”) and CATABASIS PHARMACEUTICALS, INC., a Delaware corporation having a mailing address at One Kendall Square, Building 1400, Suite B14202, Cambridge, Massachusetts 02139 (“Tenant”).

January 29th, 2021
Catabasis Pharmaceuticals IncAGREEMENT AND PLAN OF MERGER by and among CATABASIS PHARMACEUTICALS, INC., CABO MERGER SUB I, INC., CABO MERGER SUB II, LLC, and QUELLIS BIOSCIENCES, INC. Dated as of January 28, 2021

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of January 28, 2021, by and among CATABASIS PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), CABO MERGER SUB I, INC., a Delaware corporation (“First Merger Sub”), CABO MERGER SUB II, LLC, a Delaware limited liability company (“Second Merger Sub” and together with First Merger Sub, “Merger Subs”), and QUELLIS BIOSCIENCES, INC., a Delaware corporation (the “Company”).

August 10th, 2017
Catabasis Pharmaceuticals IncFOURTH AMENDMENT OF LEASE

THIS FOURTH AMENDMENT OF LEASE (this “Amendment”) is made as of this 7 day of August, 2017, by and between ARE-MA REGION NO. 59, LLC, a Delaware limited liability company, having an address at c/o Alexandria Real Estate Equities, Inc., 385 East Colorado Boulevard, Suite 299, Pasadena, California 91101 (“Landlord”), and CATABASIS PHARMACEUTICALS, INC., a Delaware corporation, having a mailing address at One Kendall Square, Building 1400E, Suite B14202, Cambridge, Massachusetts 02139 (“Tenant”).

April 1st, 2016
Catabasis Pharmaceuticals IncCONSULTING AGREEMENT

THIS CONSULTING AGREEMENT (the “Agreement”), made this 31st day of March, 2016, is entered into by Catabasis Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at One Kendall Square, Suite B14202, Cambridge, MA 02139 (the “Company”), and Ian C. Sanderson, who resides at 127 Lincoln Road, Lincoln, MA 01773 (the “Consultant”).

November 12th, 2015
Catabasis Pharmaceuticals IncSECOND AMENDMENT OF LEASE,

THIS SECOND AMENDMENT OF LEASE (this “Amendment”) is effective as ofthe 16th day of July, 2015 (the “Effective Date”), by and between DWF IV ONE KENDALL, LLC, a Delaware limited liability company having an address c/o Divco West Real Estate Services, Inc., One Kendall Square, Cambridge, Massachusetts 02139, Attention: Property Manager (“Landlord”) and CATABASIS PHARMACEUTICALS, INC., a Delaware corporation having a mailing address at One Kendall Square, Building 1400, Suite B14202, Cambridge, Massachusetts 02139 (“Tenant”).

May 12th, 2022
Astria Therapeutics, Inc.ASTRIA THERAPEUTICS, INC. NONSTATUTORY STOCK OPTION AGREEMENT

This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.

June 3rd, 2015
Catabasis Pharmaceuticals IncCATABASIS PHARMACEUTICALS, INC. INCENTIVE STOCK OPTION AGREEMENT

This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.

January 29th, 2021
Catabasis Pharmaceuticals IncSTOCK PURCHASE AGREEMENT

This Stock Purchase Agreement (this “Agreement”) is dated as of January 28, 2021, by and among Catabasis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

February 22nd, 2022
Astria Therapeutics, Inc.ASTRIA THERAPEUTICS, INC. Nonstatutory STOCK OPTION AGREEMENT Granted Under 2022 Inducement Stock Incentive Plan

This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.

October 16th, 2018
Catabasis Pharmaceuticals IncSUBLEASE AGREEMENT BY AND BETWEEN CATABASIS PHARMACEUTICALS, Inc., a Delaware corporation, as Sublandlord and INZEN THERAPEUTICS, INC., a Delaware corporation, as Subtenant One Kendall Square, Building #1400, Cambridge, MA Dated as of September 14, 2018

Master Lease: That certain Lease Agreement dated December 17, 2010 (“Original Lease”) by and between RB Kendall Fee, LLC (“RB Kendall”), as landlord, and Sublandlord, as tenant, as amended by that certain Commencement Date Agreement dated as of April 15, 2011 (the “Commencement Date Agreement”) by and between RB Kendall, as landlord, and Sublandlord, as tenant, as further amended by that certain First Amendment of Lease dated as of December 21, 2011 (“First Amendment”) by and between RB Kendall, as landlord, and Sublandlord, as tenant, as further amended by that certain Second Amendment of Lease dated as of July 16, 2015 (“Second Amendment”) by and between DWF IV One Kendall, LLC (“DWF”), as successor to RB Kendall, as landlord, and Sublandlord, as tenant, as further amended by that certain Acknowledgement of Second Expansion Premises Commencement Date and Agreement dated as of September 3, 2015 by and between DWF, as landlord, and Sublandlord, as tenant, as further amended by that cer

March 15th, 2016
Catabasis Pharmaceuticals IncSECOND AMENDMENT TO CREDIT AND SECURITY AGREEMENT

SECOND AMENDMENT TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is dated as of December 22, 2015, by and among CATABASIS PHARMACEUTICALS, INC., a Delaware corporation (the “Borrower”), the Lenders party to the Credit Agreement described below and MIDCAP FINANCIAL TRUST, a Delaware statutory trust (“MidCap”), as administrative agent (in such capacity, “Agent”).

May 12th, 2022
Astria Therapeutics, Inc.ASTRIA THERAPEUTICS, INC. INCENTIVE STOCK OPTION AGREEMENT

This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.